This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
Fresenius Medical Launches 4008A Dialysis Machine in China
by Zacks Equity Research
Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.
Align Technology Inks Distribution Deal With Zimmer Biomet
by Zacks Equity Research
This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.
PRA Health Simplifies Treatment Decisions With Metys Launch
by Zacks Equity Research
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
Here's Why You Should Retain Pacific Biosciences For Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.
Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
by Zacks Equity Research
Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.
Abbott Receives European Nod for Pediatric Heart Devices
by Zacks Equity Research
Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.
Intersect ENT Rides on Innovation Amid Pricing Concerns
by Zacks Equity Research
The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.
HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set
by Zacks Equity Research
HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.
Here's Why You Should Retain OPKO Health (OPK) Stock For Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.
Varian's ProBeam Now Available in Multi-Room Configuration
by Zacks Equity Research
Shandong Cancer Hospital in China selects Varian (VAR) to equip its new research center with the ProBeam Proton Therapy system.
Medtronic Collaborates With Novo Nordisk for Diabetes Care
by Zacks Equity Research
This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
by Zacks Equity Research
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
Here's Why You Should Retain Patterson Companies (PDCO) Now
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
by Zacks Equity Research
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Medtronic (MDT) Earns Dow Jones Sustainability Recognition
by Zacks Equity Research
Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.
BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
by Zacks Equity Research
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
by Zacks Equity Research
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
BAX or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
CryoLife Enters Agreement With Endospan for Aortic Stent
by Zacks Equity Research
CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.
Medidata (MDSO) Collaborates With Mapi Research to Boost Rave
by Zacks Equity Research
Medidata's (MDSO) latest collaboration is expected to solve major eCOA implementation struggles in the pharmaceutical industry.